A splashy recent acquisition by the company might not be panning out.Disappointing news from the laboratory weighed on AbbVie (ABBV -12.53%) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not do well in recent testing. On the company's latest readout, investors were aggressively trading out of the shares, leaving them with a 12% decline in late-afternoon trading.Schizophrenia drug didn't do well in the labJust before the market op ...